We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+3.58%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$69.4B
AUM Growth
+$3.54B
Cap. Flow
+$1.44B
Cap. Flow %
2.08%
Top 10 Hldgs %
21.44%
Holding
3,843
New
225
Increased
1,690
Reduced
1,576
Closed
217

Sector Composition

Rank Sector Weight
1 Technology 10.52%
2 Financials 9.29%
3 Healthcare 8.12%
4 Industrials 6.67%
5 Consumer Discretionary 5.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PCRX icon
2876
Pacira BioSciences
PCRX
$974M
$356K ﹤0.01%
8,188
-11,675
-59% -$496K
SWBI icon
2877
Smith & Wesson
SWBI
$636M
$356K ﹤0.01%
51,416
-910
-2% -$6.45K
AEIS icon
2878
Advanced Energy
AEIS
$12.6B
$355K ﹤0.01%
6,305
-124
-2% -$6.64K
PSCD icon
2879
Invesco S&P SmallCap Consumer Discretionary ETF
PSCD
$24M
$355K ﹤0.01%
5,969
+787
+15% +$47.3K
GTX icon
2880
Garrett Motion
GTX
$5.41B
$354K ﹤0.01%
23,038
+788
+4% +$13.4K
IFLN
2881
Invesco Bloomberg Enhanced Fallen Angels ETF
IFLN
$306M
$354K ﹤0.01%
18,705
-11,609
-38% -$218K
ZTR
2882
Virtus Total Return Fund
ZTR
$337M
$354K ﹤0.01%
30,445
+618
+2% +$6.87K
PIM
2883
Franklin Master Intermediate Income Trust
PIM
$153M
$353K ﹤0.01%
76,845
+15,606
+25% +$70.8K
AIR icon
2884
AAR Corp
AIR
$5.74B
$351K ﹤0.01%
9,528
-2,454
-20% -$81.2K
VERU icon
2885
Veru
VERU
$44.5M
$351K ﹤0.01%
16,500
+4,000
+32% +$67.8K
MYOK
2886
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$347K ﹤0.01%
6,923
+742
+12% +$36.1K
LHX icon
2887
CALL
L3Harris
LHX
$54B
$346K ﹤0.01%
24,200
-900
-4% -$162K
MIN
2888
Aberdeen Intermediate Income Fund
MIN
$278M
$346K ﹤0.01%
89,664
+19,164
+27% +$72.2K
MRC
2889
DELISTED
MRC Global
MRC
$346K ﹤0.01%
20,235
-1,356
-6% -$22.8K
PBR icon
2890
Petrobras
PBR
$118B
$346K ﹤0.01%
22,200
-138,707
-86% -$2.12M
DB icon
2891
Deutsche Bank
DB
$71.9B
$345K ﹤0.01%
45,165
+5,912
+15% +$45.6K
SCL icon
2892
Stepan Co
SCL
$1.47B
$345K ﹤0.01%
3,752
-3,774
-50% -$337K
EWY icon
2893
iShares MSCI South Korea ETF
EWY
$25.2B
$341K ﹤0.01%
5,697
-1,967
-26% -$117K
FRO icon
2894
Frontline
FRO
$8.56B
$341K ﹤0.01%
42,060
-7,189
-15% -$57.2K
HMN icon
2895
Horace Mann Educators
HMN
$2.13B
$341K ﹤0.01%
8,456
+285
+3% +$11.2K
RDN icon
2896
Radian Group
RDN
$4.87B
$341K ﹤0.01%
+14,921
New +$340K
GBX icon
2897
The Greenbrier Companies
GBX
$1.43B
$340K ﹤0.01%
11,194
GOOD
2898
Gladstone Commercial Corp
GOOD
$618M
$340K ﹤0.01%
16,032
+4,512
+39% +$95.9K
OUSM icon
2899
ALPS O'Shares US Small-Cap Quality Dividend ETF
OUSM
$880M
$340K ﹤0.01%
12,396
+256
+2% +$6.92K
RING icon
2900
iShares MSCI Global Gold Miners ETF
RING
$2.45B
$340K ﹤0.01%
16,640
+4,797
+41% +$83.3K

Similar funds

Raymond James & Associates's Q2 2019 Portfolio in Review

As of Q2 2019, Raymond James & Associates held 3,843 positions worth $69.4B, up 5.4% from $65.8B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Raymond James & Associates's Q2 2019 filing shows 225 new, 1,690 increased, 1,576 reduced and 217 closed positions. Its largest new stake was Dow Inc: 851,378 shares worth $42M. The largest sale was AbbVie, an estimated $134M.

By sector, the portfolio is most concentrated in Technology at 11% of assets, up from 11% a quarter earlier, followed by Financials and Healthcare.

  • Raymond James & Associates's largest Q2 2019 buy was Dow Inc: 851,378 shares worth $42M.
  • Raymond James & Associates added most to Medtronic in Q2 2019, an estimated $157M increase.
  • Raymond James & Associates's biggest Q2 2019 reduction was AbbVie, cutting an estimated $134M.
  • Raymond James & Associates fully exited Ultimate Software Group Inc in Q2 2019, selling an estimated $5.43M.
  • Raymond James & Associates's ten largest holdings make up 21% of its $69.4B portfolio in Q2 2019.
  • Raymond James & Associates opened 225 new positions and closed 217 in Q2 2019.
  • Raymond James & Associates's portfolio value rose 5.4% quarter-over-quarter to $69.4B.

Based on Raymond James & Associates's 13F filing for Q2 2019, filed 6 Aug 2019.